ABSTRACT
INTRODUCTION We investigated whether depression modified the associations between sleep duration and cognitive performance.
METHODS Multivariable linear regression models examined the associations between sleep duration and cognition in 1,853 dementia- and stroke-free participants from the Framingham Heart Study. Participants were categorized in four groups: no depressive symptoms, no antidepressants; depressive symptoms without antidepressants use; antidepressant use without depressive symptoms; both depressive symptoms and antidepressant use.
RESULTS Long sleep was associated with reduced overall cognitive function. Strong associations between sleep duration and cognitive performance were found in individuals with depressive symptoms, regardless of antidepressant use. Weaker but significant effects were observed in those without depressive symptoms. No significant associations were observed in participants using antidepressants without depressive symptoms.
DISCUSSION These findings provide new evidence that sleep duration may be a modifiable risk factor for cognitive decline, particularly in individuals with depressive symptoms. Future research should elucidate underlying mechanisms and temporal relationships.
RESEARCH IN CONTEXT Systematic review: We conducted a systematic search on PubMed and Google Scholar for peer-reviewed articles using keyword combinations related to sleep, cognition, and depression. Existing evidence reveals mixed findings on the relationship between sleep duration and cognition, with limited studies examining the role of depression on this association.
Interpretation: We observed that only long sleep duration (≥9h) was associated with poorer global cognition, executive function, visuospatial memory, and verbal learning/memory. Depression moderated this association, showing stronger negative effects of long sleep on cognition in individuals with depressive symptoms, regardless of antidepressant use. This suggests that long sleep duration may serve as an early indicator or risk factor for cognitive decline in those with depressive symptoms.
Future directions: Longitudinal studies with objective and subjective sleep assessments across diverse populations are needed to clarify how depression and its treatment influence the relationship between sleep duration and cognitive decline and support clinical strategies.
HIGHLIGHTS
Sleeping ≥ 9hours/night was associated with worse cognitive performance.
This association was stronger among those with depression.
Long sleepers were more likely to report symptoms of depression.
Sleep may be a modifiable risk for cognitive decline in people with depression.
Competing Interest Statement
Dr. Seshadri reports consulting for Eisai and Biogen. Dr. Baril reports speaking fees from Eisai. Dr. Salardini reports speaking fees from Lilly.
Funding Statement
The Framingham Heart Study was supported by grants from the National Heart, Lung, and Blood Institute (contract No. N01-HC-25195, No. HHSN268201500001I, and No. 75N92019D00031), the National Institute on Aging (R01 AG054076, R01 AG049607, U01 AG052409, R01 AG059421, RF1 AG063507, RF1 AG066524, U01 AG058589), and the National Institute of Neurological Disorders and Stroke (R01 NS017950 and UH2 NS100605). This work was made possible by grants from the National Institute of Health (P30 AG066546), the National Institute of Aging (AG0623531), and the Alzheimer s Association. Dr. Baril is supported by the Sleep Research Society Foundation, the Fonds de recherche du Quebec en Sante, the Canadian Institutes of Health Research, and the Alzheimer Society of Canada. Dr. Pase is supported by a National Health and Medical Research Council of Australia Investigator Grant (GTN2009264). Dr. Himali is supported by an endowment from the William Castella family as William Castella Distinguished University Chair for Alzheimer s Disease Research, and Dr. Seshadri by an endowment from the Barker Foundation as the Robert R Barker Distinguished University Professor of Neurology, Psychiatry and Cellular and Integrative Physiology. Drs. Seshadri and Himali receive support from The Bill and Rebecca Reed Endowment for Precision Therapies and Palliative Care.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board at Boston Medical Center gave ethical approval for this work. All participants signed the informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.